# Launch Excellence and Market Access
A drug can win approval from the FDA (the U.S. Food and Drug Administration, which decides whether a medicine is safe and effective enough to sell) and still fail commercially. Why? Because a physician who wants to prescribe it discovers the patient's insurer will not pay for it, or demands they try two cheaper drugs first. Approval gets you permission to sell. It does not get you sold.
This gap between "approved" and "paid for" is where pharma marketing lives, and it explains why launch is the highest-stakes moment in a product's life.
In many therapy areas, a drug's trajectory in its first six to twelve months predicts its performance for years. Prescribing habits harden. Formulary decisions (an insurer's list of covered drugs) get locked in. Competitors who launch first can define what "good" looks like before you arrive.
You also have a ticking clock. A patent gives roughly 20 years of protection from filing, but much of that is consumed by development and trials. By the time a drug launches, only a portion of exclusive-selling time may remain before generic or biosimilar copies arrive. Every quarter of a slow launch is revenue you never recover.
So launch is not a marketing "campaign." It is a coordinated commercial operation with one shot to get it right.
In consumer marketing, the person who wants the product usually pays for it. Pharma breaks that link.
Consider who is involved in a single prescription:
The payer holds the money, and often the real power. In the U.S., pharmacy benefit managers (PBMs), the middlemen who negotiate drug coverage for insurers and employers, can decide whether your drug sits on a preferred tier (low patient co-pay) or a punitive tier (high co-pay, prior authorization paperwork). In countries with national systems, a government body may simply decline to fund a drug it judges too expensive for the benefit it delivers.
This is why "the payer is the customer." You can generate all the physician awareness in the world, but if the payer blocks access, prescriptions stall.
Market access is the discipline of getting a drug reimbursed and available to patients at a viable price. It sits alongside traditional marketing and, at launch, often outranks it.
Market access teams answer questions like:
In the UK, for example, the National Institute for Health and Care Excellence (NICE) appraises whether the health service should fund a drug based on its cost relative to health gained. A "no" from NICE can effectively close a market. Access teams prepare for that appraisal years in advance.
Physicians respond to clinical data. Payers respond to value: does this drug justify its cost compared to what patients use today?
The value dossier is the document that makes that case. Think of it as the payer-facing argument for your drug's worth. It typically pulls together:
A concrete example of the logic: a drug that costs more per month but keeps patients out of the hospital may be cheaper for the payer overall. That "total cost of care" story is often more persuasive to a payer than efficacy alone.
The lesson for marketers: the evidence a payer needs is not always the evidence a trial was designed to produce. Strong access planning shapes trial design early, so the data exists when the dossier is due.
The function that builds the value evidence is HEOR: Health Economics and Outcomes Research. HEOR teams generate the studies and models that populate the value dossier and support payer negotiations.
For a non-technical audience, the key idea is this: HEOR translates clinical results into the language of money and population health, which is the language payers speak. A cardiologist cares that a drug lowers cholesterol. A payer cares how many heart attacks that prevents, and what each prevented event saves.
"Launch excellence" is a real term of art in pharma, and it means orchestrating many functions to peak at the same moment. A strong launch aligns:
1. Regulatory timing. Marketing cannot promote a drug before approval, and promotion is tightly restricted to the approved label (the official description of what the drug is for). Legal and regulatory review gate nearly every claim.
2. Market access readiness. Value dossiers, payer negotiations, and pricing decisions must be locked before or at launch. Access delays waste the launch window.
3. Medical affairs. These teams share scientific data with physicians and specialists through non-promotional channels, building clinical understanding ahead of and during launch.
4. Sales force deployment. Reps need to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → the right prescribers with an approved message, and know which payers cover which patients.
5. Supply chain. The drug must physically be available. A stockout at launch is a self-inflicted wound.
6. Patient support. Co-pay assistance, adherence programs, and navigation help patients actually start and stay on therapy, especially when prior authorizations create friction.
Miss on any one of these and the others underdeliver. A brilliant campaign fails if the drug is not on formulary. Perfect access fails if the sales force is not trained. Launch excellence is fundamentally a coordination problem.
Knowledge check
1. Why can a drug receive FDA approval and still fail commercially?
2. Why is the launch window considered the highest-stakes moment in a drug's life?
3. In pharma, why is the payer often described as the 'real customer' rather than the patient?
4. Select ALL correct answers about why the shrinking patent-exclusivity window matters at launch.
Select all the correct answers.
5. Select ALL correct answers describing the distinct roles involved in a single prescription.
Select all the correct answers.
The playbook shifts with the situation:
Matching your launch model to the archetype is a core strategic judgment. Spending like a mass-market launch on a rare disease drug wastes money; treating a crowded market like a first-in-class opportunity underinvests in the contracting fight.
Everything above happens inside strict rules. In the U.S., promotional claims must be consistent with the approved label and fairly balanced with risk information. The FDA's Office of Prescription Drug Promotion oversees this. Value dossiers shared with payers follow their own evidence standards. Marketers in pharma work hand in glove with legal and regulatory colleagues, not around them.
This is why pharma marketing is a specialist discipline. The creative freedom of consumer marketing does not exist here, and pretending otherwise creates real legal risk.